

a
mouse anti-PD-1 (αPD-1, 250μg/dose)
Tivalimogene teraplasmid (GX-188E, 0.4μg/dose)
Efineptakin alfa (NT-I7, 295μg/dose)
C57BL/6
(Female)
5x10^5 (Subcutaneous)
hE6/E7-Expressed TC-1
scRNA-seq
IHC
Day -6 0 1 2 3 4 5 6 7 9 11 13 15 17 19 21 23 25
Tumor
Lymph Node
Tumor
scRNA Sequencing (Day 9)
Dissociation
Library scRNA/TCR
Histology (Day 25)
FFPE H&E IHC
b
Tumor Size (mm3)
Groups
Control
αPD-1
GX-188E
NT-I7
GX-188E+αPD-1
GX-188E+NT-I7
GX-188E+αPD-1+NT-I7
c
Overall survival (%)
0.5251
0.069
0.0144 *
0.0001 ****
d
% area of CD8 IHC (quantified by ImageJ)
n.s
e
UMAP1
UMAP2
Cell
CD8+-Naïve
CD8+-CM
CD8+Gzmm+-EM
CD8+Klrb1c+-EM
CD8+Cd44+
CD8+Tnfrsf9+
CD8+ISG+
CD8+-Tex
CD8+-Proliferating
f
Initiation
Early
Intermediate
Terminal
Cell type distribution
Pseudotime
Celltype
CD8+Tnfrsf9+
CD8+ISG+
CD8+TEX
CD8+-Proliferating
g
Tumor CD8+T cell proportion
h
Stemness score
Exhaustion score
Cell order along CD8+

Figure 1.